Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue
Read More 4 minute read Pharma Industry News AbbVie to acquire Capstan Therapeutics for $2.1bn to expand in vivo CAR-T platform for autoimmune therapy AbbVie will acquire Capstan Therapeutics for $2.1B, gaining in vivo CAR-T platform and lead asset CPTX2309 in autoimmune therapy. Read full acquisition details. byPallavi MadhirajuJuly 2, 2025